References
- Berman J. D., Gallalee J. F., Gallalee J. V. Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am. J. Trop. Med. Hyg (1988); 39: 41–45
- Bradley D. J., Kirkley J. Regulation of Leishmania populations within the host. I The variable course of Leishmania donovani infections in mice. Clin. Ex. Immunol (1977); 30: 119–129
- Brewer J. M., Alexander J. The adjuvant activity of non‐ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunol (1993); 75: 570–575
- Carter K. C., Baillie A. J., Alexander J., Dolan T. F. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with L. donovani is organ dependent. J. Pharm. Pharmacol (1988); 40: 370–373
- Carter K. C., Dolan T. F., Baillie A. J., Alexander J. The limitations of carrier mediated sodium stibogluconate chemotherapy in a BALB/c mouse model of visceral leishmaniasis. Liposomes in the therapy of infectious diseases and cancer, G. Lopez‐Berestein, I. J. Fiddler. Alan R. Liss Inc. (1989a); 215–226
- Carter K. C., Dolan T. F., Alexander J., Baillie A. J., McColgan C. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol (1989b); 41: 87–91
- Collins M. Manipulation of antimony disposition in vivo by the administration of carrier formulations of sodium stibogluconate. PhD Thesis, University of Strathclyde. 1993
- Davidson R. N., Croft S. L. Recent advances in the treatment of visceral leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg (1993); 87: 130–131; 141
- Fulton J. D. Treatment of Leishmania donovani infections with surface‐active agents. Nature (1960); 187: 1129–1130
- Israelachvili J. Aggregation of amphiphilic molecules into micelles, bilayers, vesicles and biological membranes. Intermolecular and surface forces, J. Israelachvili. Academic Press. (1992); 366–394
- Modabber F. Leishmaniasis. Tropical Diseases Research Progress 1991–2, R. Walgate, K. Simpson. WHO, Geneva 1993
- Olliaro P. L., Bryceson A. D.M. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today (1993); 9: 323–328
- Ozer A. Y., Hincal A. A., Bouwstra J. A. A novel drug delivery system: non‐ionic surfactant vesicles. Eur. J. Pharm. Biopharm (1991); 37: 75–79
- Rees P. H., Keating M. I., Kager P. A., Hockmeyer W. T. Renal clearance of pentavalent antimony‐sodium stibogluconate. Lancet (1980); 2: 226–229, TDR (1993). News No. 43 October 1993, 1–4
- Wickramsinghe S. N., Abdalla S. H., Kaisili E. G. The ultra structure of bone marrow in patients with visceral leishmaniasis. J. Clin. Pathol (1987); 40: 267–275